Trials evaluating T-cells targeting HLA-restricted PRAME peptides have demonstrated promising anti-tumor activity in PRAME-positive solid tumors, including SS: in the Phase 1b ACTengine IMA203 trial, all three SS patients achieved tumor shrinkage, including one objective response [78]. Here, PRAME is linked to neoplasm.